Selective Elimination of TP53 Mutant Cells by Transcript-Activated Chromatin Shredding

Area of Science:

• Biochemistry
• Molecular Biology
• Genetics

Background:

• Genetic mutations in tumor suppressor proteins, like p53, drive cancer development.
• Current cancer therapies struggle to target these mutations due to a lack of drug-binding pockets.
• Restoring the function of mutated tumor suppressor proteins remains a significant challenge in cancer treatment.

Purpose of the Study:

• To develop a novel method for selectively killing cancer cells by targeting cancer-specific transcripts.
• To investigate the potential of CRISPR-Cas12a2 in treating cancers with undruggable mutations.
• To establish transcript-activated chromatin shredding as a new therapeutic paradigm.

Main Methods:

• Programmed CRISPR-Cas12a2, an RNA-guided nuclease, to target cancer-specific RNA sequences.
• Utilized the trans-nucleolytic cleavage activity of Cas12a2 to induce chromatin cleavage.
• Triggered DNA damage and subsequent cell death in cancer cells through targeted chromatin shredding.

Main Results:

• Demonstrated that RNA-guided Cas12a2 can selectively identify and target cancer-specific RNA signatures.
• Showcased the ability of Cas12a2 to induce trans chromatin cleavage, leading to DNA damage and cancer cell death.
• Validated transcript-activated chromatin shredding as a viable strategy for targeting previously undruggable mutations.

Conclusions:

• CRISPR-Cas12a2 can be programmed to selectively eliminate cancer cells by targeting their unique RNA.
• Transcript-activated chromatin shredding represents an innovative approach for precision medicine.
• This method holds promise for developing novel treatments for cancers with undruggable genetic mutations.